INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged securities fraud and unlawful business practices following the failure of a key clinical trial [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Vistagen and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 16, 2026, to request to be appointed as Lead Plaintiff if they purchased Vistagen securities during the Class Period [2]. Group 2: Clinical Trial Outcome - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for treating social anxiety disorder did not show statistically significant improvement on the primary endpoint [4]. - The trial results indicated no treatment difference between fasedienol and placebo for the secondary endpoint [4]. Group 3: Stock Price Impact - Following the announcement of the trial results, Vistagen's stock price fell by $3.499 per share, representing an 80.25% decline, closing at $0.861 per share on December 17, 2025 [5].